Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.55 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27941733 | 0.84 | ALDH1A1 (0.47) | CTSSPDK2PDK1PDK3PDK4 | |
| SCHEMBL45490 | 0.82 | LMNA (0.59) | PDK2LMNAGAATSHRCFTR | |
| SCHEMBL1508457 | 0.81 | LMNA (0.50) | CTSSPDK2PDK1PDK3PDK4 | |
| SCHEMBL5239843 | 0.81 | CTSS (0.51) | CTSSPDK2LMNAGAATSHR | |
| SCHEMBL726068 | 0.81 | TAS2R14 (0.54) | CTSSPDK2PDK1PDK3PDK4 | |
| SCHEMBL9524633 | 0.81 | CTSS (0.56) | CTSSCTSKP2RX7LMNAGAA | |
| SCHEMBL30562236 | 0.81 | CTSS (0.56) | CTSSCTSKP2RX7LMNAGAA | |
| SCHEMBL28311763 | 0.80 | CTSS (0.55) | CTSSCTSKP2RX7LMNAGAA | |
| SCHEMBL20267168 | 0.80 | ALDH1A1 (0.57) | CTSSPDK2CTSKP2RX7LMNA | |
| SCHEMBL7984064 | 0.80 | CTSS (0.63) | CTSSPDK2CTSKP2RX7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851072-B2 | Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851072-B2 | Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190308947-A1 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-10 | — | — | US | disclosed |
| US-20190308947-A1 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-10 | — | — | US | disclosed |
| WO-2019195641-A2 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195641-A2 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-10 | — | — | WO | disclosed |
| CN-106543143-B | A kind of novel FLT3 kinase inhibitor and application thereof | 合肥中科普瑞昇生物医药科技有限公司 | 2019-03-22 | — | — | CN | disclosed |
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-05 | — | — | US | disclosed |
| WO-2003048121-A1 | THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| EP-1289971-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092241-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-06 | — | — | WO | disclosed |
| CN-1137035-A | Basic group substituted benzoyl guanidine, its preparing process, its use as medicine or diagnostic reagent, and medicine containing the same | HOECHST AG (DE) | 1996-12-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | APOB, APOL1, CETP | CTSS 701/4885PDK2 4600/4885PDK1 4107/4885 |
| US-20190308947-A1 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | RHOXF2, BPTF, SREBF1 | CTSS 3355/4885PDK2 3223/4885PDK1 2930/4885 |
| US-10851072-B2 | Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same | RHOXF2, BPTF, SREBF1 | CTSS 3355/4885PDK2 3223/4885PDK1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.